{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:20:16Z","timestamp":1791613216339,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ijantimicag.2020.105982","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T10:52:47Z","timestamp":1587034367000},"page":"105982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":205,"title":["Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-4641","authenticated-orcid":false,"given":"Ming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.105982_bib0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. Lancet"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0002","first-page":"E005","article-title":"[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0005","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.50577","article-title":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID\u201019)","author":"Zha","year":"2020","journal-title":"Med J Aust"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0007","first-page":"133","article-title":"Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7)","year":"2020","journal-title":"Chin Med J"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0012","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0013","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0014","unstructured":"Xu XL, Han MF, Li TT, Sun W, Wang DS, Fu BQ, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv:202003.00026."},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0015","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0016","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3109\/s10165-012-0780-0","article-title":"Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab","volume":"23","author":"Kawada","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0017","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0018","first-page":"38","article-title":"Comprehensive treatment and management of corona virus disease 2019: expert consensus statement from Shanghai","year":"2020","journal-title":"Chin J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105982_bib0019","article-title":"Effect of ulinastatin on interleukins and pulmonary function in bypass patients: a meta-analysis of randomized controlled trials","author":"He","year":"2018","journal-title":"Herz"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:48Z","timestamp":1760377068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920301394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0924857920301394"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105982","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105982"}}